Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites

Journal of Virology

Volumn 70, Issue 12, 1996, Pages 8431-8437

  Watkins, Brynmor A ^a   Buge, Suzan ^a   Aldrich, Kristine ^a   Davis, Alberta E ^a   Robinson, James ^b   Reitz Jr , Marvin S ^a,c   Robert Guroff, Marjorie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIGEN BINDING; ARTICLE; BINDING SITE; ENVELOPE GENE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE; VIRUS ENVELOPE; VIRUS MUTATION; VIRUS REPLICATION;

EID: 0029861654     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.12.8431-8437.1996     Document Type: Article

References (54)

1. Albert, J., B. Abrahamsson, K. Nagy, E. Aurelius, H. Gaines, G. Nystrom, and E. M. Fenyo. 1990. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4:107-112.
2. Chanh, T. C., G. R. Dreesman, P. Kanda, G. P. Linette, J. T. Sparrow, D. D. Ho, and R. C. Kennedy. 1986. Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J. 5:3065-3071.
3. Dalgleish, A. G., T. C. Chanh, R. C. Kennedy, P. Kanda, P. R. Clapham, and R. A. Weiss. 1988. Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. Virology 165:209-215.
4. Fisher, A. G., E. Collati, L. Ratner, R. C. Gallo, and F. Wong-Staal. 1985. A molecular clone of HTLV-III with biologic activity. Nature (London) 316: 262-265.
5. Freed, E. O., and M. A. Martin. 1994. Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotcin gp120. J. Virol. 68:2503-2512.
6. Fultz, P. N., P. L. Nara, F. Barre-Sinoussi, A. Chaput, M. L. Greenberg, E. Muchmore, M.-P. Kieny, and M. Girard. 1992. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science 256:1687-1690.
7. Fung, M. S., C. R. Sun, W. L. Gordon, R. S. Liou, T. W. Chang, W. N. Sun, E. S. Daar, and D. D. Ho. 1992. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J. Virol. 66:848-856.
8. Gorny, M. K., A. J. Conley, S. Karwowska, A. Buchbinder, J. Xu, E. A. Emini, S. Koenig, and S. Zolla-Pazner. 1992. Neutralization of diverse HIV-1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66:7538-7542.
9. Gorny, M. K., J. P. Moore, A. J. Conley, S. Karwowska, J. Sodroski, C. Williams, S. Burda, L. J. Boots, and S. Zolla-Pazner. 1994 Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J. Virol. 68:8312-8320.
10. Goudsmit, J., C. Debouck, R. H. Meloen, L. Smit, M. Bakker, D. M. Asher, A. V. Wolff, C. J. Gibbs, Jr., and C. Gadjusek. 1988. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc. Natl. Acad. Sci. USA 85:4478-4482.
11. Haigwood, N. L., C. B. Barker, K. W. Higgins, P. V. Skiles, G. K. Moore, K. A. Mann, D. R. Lee, J. W. Eichberg, and K. S. Steimer. 1990. Evidence for neutralizing antibodies directed against conformational epitopes of HIV-1 gp120, p. 313-320. In R. M. Chanock, H. Ginsberg, and R. A. Lerner (ed.), Vaccines 1990: modern approaches to new vaccines including prevention of AIDS. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
12. Ho, D. D., M. S. Fung, Y. Z. Cao, X. L. Li, C. Sun, T. W. Chang, and N. C. Sun. 1991. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc. Natl. Acad. Sci. USA 88:8949-8952.
13. Ho, D. D., J. C. Kaplan, I. E. Rackauskas, and M. E. Gurney. 1988. Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. Science 239:1021-1023.
14. Javaherian, K., A. J. Langlois, G. J. LaRosa, A. T. Profy, D. P. Bolognesi, W. C. Herlihy, S. D. Putney, and T. J. Matthews. 1990. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 250:1590-1593.
15. Javaherian, K., A. J. Langlois, C. McDanal, K. L. Ross, L. I. Eckleer, C. L. Jellis, A. T. Profy, J. R. Rusche, D. P. Bolognesi, S. D. Putney, and T. J. Matthews. 1989. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. Natl. Acad. Sci. USA 86:6768-6772.
16. Klasse, P. J., J. A. McKeating, M. Schutten, M. S. Reitz, Jr., and M. Robert-Guroff. 1993. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env: Ala[→Thr]) decreases viral neutralization by monoclonal antibodies to the CD4 binding site. Virology 196:332-337.
17. Laman, J. D., M. M. Schellekens, Y. H. Abacioglu, G. K. Lewis, M. Termette, R. A. M. Fouchier, J. P. M. Langedyk, E. Claassen, and W. J. A. Boersma. 1992. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain. J. Virol. 66:1823-1831.
18. Lemasson, I., V. Housset, B. Calas, and C. Devaux. 1995. Antigenic analysis of HIV type 1 external envelope (env) glycoprotein C2 region: implication for the structure of env. AIDS Res. Hum. Retroviruses 11:1177-1186.
19. Matsushita, S., M. Robert-Guroff, J. Rusche, A. Koito, T. Hattori, H. Hoshino, K. Javaharian, K. Takalsuki, and S. Putney. 1988. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J. Virol. 62:2107-2114.
20. Matthews, T. J., A. J. Langlois, W. G. Robey, N. T. Chang, R. C. Gallo, P. J. Fischinger, and D. P. Bolognesi. 1986. Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc. Natl. Acad. Sci. USA 83:9709-9713.
21. McKeating, J. A., J. Gow, J. Goudsmit, L. H. Pearl, C. Mulder, and R. A. Weiss. 1989. Characterization of HIV-1 neutralization escape mutants. AIDS 3:777-784.
22. Moore, J. P. 1990. Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4. AIDS 4:297-305.
23. Moore, J. P., and D. D. Ho. 1993. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J. Virol. 67:863-875.
24. Moore, J. P., Q. J. Sattentau, H. Yoshiyama, M. Thali, M. Charles, N. Sullivan, S. W. Poon, M. S. Fung, F. Traincard, M. Pinkus, G. Robey, J. E. Robinson, D. D. Ho, and J. Sodroski. 1993. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains. J. Virol. 67:6136-6151.
25. Moore, J. P., and J. Sodroski. 1996. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 70:1863-1872.
26. Moore, J. P., M. Thali, B. A. Jameson, F. Vignaux, G. K. Lewis, S. W. Poon, M. Charles, M. S. Fung, B. Sun, P. J. Durda, L. Akerbloom, B. Wahren, D. D. Ho, O. J. Sattentau, and J. Sodroski. 1993. Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop. J. Virol. 67:4785-1796.
27. Moore, J. P., R. L. Willey, G. K. Lewis, J. Robinson, and J. Sodroski. 1994. Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1. J. Virol. 68:6836-6847.
28. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Rueker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
29. Nara, P. L., and J. Goudsmit. 1990. Neutralization resistant variants of HIV-1 escape via the hypervariable immunodominant region (303-331 aa): evidence for a conformational neutralization epitope, p. 297-306. In R. M. Chanock, H. Ginsberg, and R. A. Lerner (ed.), Vaccines 1990: modern approaches to new vaccines including prevention of AIDS. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
30. Nowak, M. A., R. M. Anderson, A. R. McLean, T. F. W. Wolfs, J. Goudsmit, and R. M. May. 1991. Antigenic diversity thresholds and the development of AIDS. Science 254:963-969.
31. Pal, R., F. Veronese, B. C. Nair, R Rahman, G. Hoke, S. W. Mumbauer, and M. G. Sarngadharan. 1992. Characterization of a neutralizing monoclonal antibody to the external glycoprotein of HIV-1. Intervirology 34:86-93.
32. Palker, T. J., M. E. Clark, A. J. Langlois, T. J. Matthews, K. J. Weinhold, R. R. Randall, D. P. Bolognesi, and B. F. Haynes. 1988. Type-specific neutralization of the human immunodeficiency virus with antibodies to envencoded synthetic peptides. Proc. Natl. Acad. Sci. USA 85:1932-1936.
33. Posner, M. R., T. Hideshima, T. Cannon, M. Mukherjee, K. H. Mayer, and R. A. Byrn. 1991. An IgG human monoclonal antibody that reacts with HIV-1/gp120, inhibits virus binding to cells, and neutralizes infection. J. Immunol. 146:4325-4332.
34. Profy, A. T., P. A. Salinas, L. I. Eckler, N. M. Dunlop, P. L. Nara, and S. D. Putney. 1990. Epitopes recognized by the neutralizing antibodies of an HIV-1 infected individual. J. Immunol. 144:4641-4647.
35. Reitz, M. S., C. A. Wilson, C. Naugle, R. C. Gallo, and M. Robert-Guroff. 1988. Generation of a neutralization resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell 54:57-63.
36. Robert-Guroff, M. 1990. Neutralizing antibodies, p. 179-185. In A. Aldovini and B. Walker (ed.). Techniques in HIV research. Stockton Press, New York.
37. Robert-Guroff, M., M. S. Reitz, W. G. Robey, and R. C. Gallo. 1986. In vitro generation of an HTLV-III variant by neutralizing antibody. J. Immunol. 137:3306-3309.
38. Rusche, J. R., K. Javaharian, C. McDanal, J. Petro, D. L. Lynn, R. Grimaila, A. Langlois, R. C. Gallo, L. O. Arthur, P. J. Fischinger, D. P. Bolognesi, S. D. Putney, and T. J. Matthews. 1988. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc. Natl. Acad. Sci. USA 85:3198-3202.
39. Steimer, K. S., P. J. Klasse, and J. A. McKeeting. 1991. HIV-1 neutralization directed to epitopes other than linear V3 determinants. AIDS 5(Suppl. 2):s135-s143.
40. Steimer, K. S., C. J. Scandella, P. V. Skiles, and N. L. Haigwood. 1991. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120. Science 254:105-108.
41. Stern, T. L., M. S. Reitz, and M. Robert-Guroff. 1995. Spontaneous reversion of human immunodeficiency virus type-1 neutralization resistant variant HXB2thr582: in vitro selection against cytopathicity highlights gp120-gp41 interactive regions. J. Virol. 69:1860-1867.
42. Sullivan, N., M. Thali, C. Furman, D. D. Ho, and J. Sodroski. 1993 Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. J. Virol. 67:3674-3679.
43. Thali, M., M. Charles, C. Furman, L. Cavacini, M. Posner, J. Robinson, and J. Sodroski. 1994. Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change. J. Virol. 68:677-680.
44. Thali, M., C. Furman, D. D. Ho, J. Robinson, S. Tilley, A. Pinter, and J. Sodroski. 1992. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 66:5635-5641.
45. Thali, M., J. P. Moore, C. Furman, M. Charles, D. D. Ho, J. Robinson, and J. Sodroski. 1993. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralizing epitopes exposed upon gp120-CD4 binding. J. Virol. 67:3978-3988.
46. Thali, M., U. Olshevsky, C. Furman, D. Gabuzda, M. Posner, and J. Sodroski. 1991. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J. Virol. 65:6188-6193.
47. IIIB isolated from an infected laboratory worker. J. Biol. Chem. 268:25894-25901.
48. Watkins, B. A., A. E. Davis, F. Cocchi, and M. S. Reitz. 1993. A rapid method for site-specific mutagenesis using larger plasmids as templates. BioTechniques 15:700-704.
49. Watkins, B. A., and M. S. Reitz, Jr. 1996. Using the polymerase chain reaction for rapid site-specific mutagenesis in large plasmids. Methods Mol. Biol. 57:217-227.
50. Watkins, B. A., M. S. Reitz, Jr., C. A. Wilson, K. Aldrich, A. E. Davis, and M. Robert-Guroff. 1993. Immune escape by human immunodeficiency virus type-1 from neutralizing antibodies: evidence for multiple pathways. J. Virol. 67:7493-7500.
51. Willey, R. L., E. K. Ross, A. J. Buckler-White, T. S. Theodore, and M. A. Martin. 1989. Functional interaction of constant and variable domains of human immunodeficiency virus type 1 gp120. J. Virol. 63:3595-3600.
52. Wilson, C. A., M. S. Reitz, Jr., K. Aldrich, P. J. Klasse, J. Blomberg, R. C. Gallo, and M. Robert-Guroff. 1990. The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute a neutralization epitope. J. Virol. 64:3240-3248.
53. Wyatt, R., J. Moore, M. Accola, E. Desjardin, J. Robinson, and J. Sodroski. 1995. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69:5723-5733.
54. Yoshiyama, H., M. Mo, J. P. Moore, and D. D. Ho. 1994. Characterization of mutants of human immunodeficiency virus type 1 that have escaped neutralization by a monoclonal antibody to the gp120 V2 loop. J. Virol. 68:974-978.